Quick Answer
CRISPR Therapeutics AG reported Total Revenue of $3.51 million for fiscal year 2025.
CRISPR Therapeutics AG — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $3.51M -90.6% |
$37.31M -89.9% |
$371.21M +30885.5% |
$1.20M -99.9% |
$914.96M +127154.9% |
$719.0K -99.8% |
| Revenue (ASC 606) | $3.51M -90.6% |
$37.31M -89.9% |
$371.21M +30885.5% |
$1.20M -99.9% |
$914.96M +127154.9% |
$719.0K -99.8% |
| Net Income | -$581.60M -58.8% |
-$366.25M -138.4% |
-$153.61M +76.4% |
-$650.17M -272.2% |
$377.66M +208.3% |
-$348.87M -621.8% |
| Diluted EPS | -$6.47 -49.1% |
-$4.34 -123.7% |
-$1.94 +76.8% |
-$8.36 -277.9% |
$4.70 +188.8% |
-$5.29 -552.1% |
| Total Assets | $2.27B +1.0% |
$2.24B +0.6% |
$2.23B -0.6% |
$2.24B -18.5% |
$2.75B +50.5% |
$1.83B +71.4% |
| Cash and Equivalents | $347.56M +16.5% |
$298.26M -23.4% |
$389.48M +83.8% |
$211.88M -77.0% |
$923.03M -21.0% |
$1.17B +23.8% |
| Stockholders Equity | $1.92B -0.5% |
$1.93B +2.6% |
$1.88B +0.4% |
$1.88B -21.8% |
$2.40B +44.2% |
$1.66B +77.2% |
| R&D Expense | $284.81M -8.2% |
$310.24M -19.9% |
$387.33M -16.1% |
$461.64M +35.6% |
$340.57M +53.8% |
$221.38M +23.4% |
| Operating Income | -$664.57M -42.4% |
-$466.57M -109.7% |
-$222.54M +66.9% |
-$673.16M -280.2% |
$373.53M +205.4% |
-$354.44M -858.3% |
| Shares Outstanding | 95.89M +11.8% |
85.74M +7.1% |
80.04M +2.0% |
78.51M +2.0% |
76.99M +4.2% |
73.91M +21.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $889.0K | +47.7% | -0.3% |
| Revenue (ASC 606) | September 30, 2025 | $889.0K | +47.7% | -0.3% |
| Net Income | September 30, 2025 | -$106.44M | -23.9% | +49.0% |
| Diluted EPS | September 30, 2025 | -$1.17 | -15.8% | +51.3% |
| Total Assets | September 30, 2025 | $2.25B | -0.5% | +10.6% |
| Cash and Equivalents | September 30, 2025 | $286.50M | +27.0% | +48.0% |
| Stockholders Equity | September 30, 2025 | $1.92B | -1.2% | +12.0% |
| R&D Expense | September 30, 2025 | $58.90M | -28.3% | -15.7% |
| Operating Income | September 30, 2025 | -$132.06M | -19.9% | +42.4% |
| Shares Outstanding | September 30, 2025 | 93.87M | +10.0% | +6.2% |
- CRISPR Therapeutics AG reported Total Revenue of $3.51 million for fiscal year 2025.
- CRISPR Therapeutics AG showed a decrease of -90.6% in Total Revenue compared to the prior fiscal year.
- CRISPR Therapeutics AG reported Revenue (ASC 606) of $3.51 million for fiscal year 2025.
- CRISPR Therapeutics AG showed a decrease of -90.6% in Revenue (ASC 606) compared to the prior fiscal year.
- CRISPR Therapeutics AG reported Net Income of -$581.60 million for fiscal year 2025.
- CRISPR Therapeutics AG showed a decrease of -58.8% in Net Income compared to the prior fiscal year.
- CRISPR Therapeutics AG reported Diluted EPS of $6.47 per share (loss) for fiscal year 2025.
- CRISPR Therapeutics AG showed a decrease of -49.1% in Diluted EPS compared to the prior fiscal year.
- CRISPR Therapeutics AG reported Total Assets of $2.27 billion for fiscal year 2025.
- CRISPR Therapeutics AG showed an increase of +1.0% in Total Assets compared to the prior fiscal year.
- CRISPR Therapeutics AG reported Cash and Equivalents of $347.56 million for fiscal year 2025.
- CRISPR Therapeutics AG showed an increase of +16.5% in Cash and Equivalents compared to the prior fiscal year.
- CRISPR Therapeutics AG reported Stockholders Equity of $1.92 billion for fiscal year 2025.
- CRISPR Therapeutics AG showed a decrease of -0.5% in Stockholders Equity compared to the prior fiscal year.
- CRISPR Therapeutics AG reported R&D Expense of $284.81 million for fiscal year 2025.
- CRISPR Therapeutics AG showed a decrease of -8.2% in R&D Expense compared to the prior fiscal year.
- CRISPR Therapeutics AG reported Operating Income of -$664.57 million for fiscal year 2025.
- CRISPR Therapeutics AG showed a decrease of -42.4% in Operating Income compared to the prior fiscal year.
- CRISPR Therapeutics AG reported Shares Outstanding of 95.89 million shares for fiscal year 2025.
- CRISPR Therapeutics AG showed an increase of +11.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: